Search research articles
Contact Us
Filters
Showing results (321-330 of 333) with videos related to
Page
of 34
Sort By:
Frontiers in Neuroscience
|
July 11, 2022
A Functional Connectome of Parkinson's Disease Patients Prior to Deep Brain Stimulation: A Tool for Disease-Specific Connectivity Analyses
Aaron Loh, Alexandre Boutet, Jürgen Germann, et al.
Journal of Medicinal Chemistry
|
August 29, 2012
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer
J Jean Cui, Michele McTigue, Mitchell Nambu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2020
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
Mi Ran Yun, Dong Hwi Kim, Seok-Young Kim, et al.
Journal of Medicinal Chemistry
|
August 5, 2011
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)
J Jean Cui, Michelle Tran-Dubé, Hong Shen, et al.
Journal of Bone Oncology
|
December 29, 2018
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
R E Coleman, M Collinson, W Gregory, et al.
Journal of Medicinal Chemistry
|
April 20, 2018
Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors
Sharan K Bagal, Kiyoyuki Omoto, David C Blakemore, et al.
Cancer Discovery
|
August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
Neurology
|
December 23, 2024
Comparison of Plasma p-tau217 and [<sup>18</sup>F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia
Kely Monica Quispialaya, Joseph Therriault, Antonio Aliaga, et al.
Journal of Medicinal Chemistry
|
May 14, 2014
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations
Ted W Johnson, Paul F Richardson, Simon Bailey, et al.
The Lancet. Oncology
|
December 2, 2024
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus
Vincent J Cogliano, Emanuela Corsini, Agnès Fournier, et al.
Page
of 34
Search research articles
Search
Showing results (321-330 of 333) with videos related to
Sort By:
Page
of 34
Frontiers in Neuroscience
|
July 11, 2022
A Functional Connectome of Parkinson's Disease Patients Prior to Deep Brain Stimulation: A Tool for Disease-Specific Connectivity Analyses
Aaron Loh, Alexandre Boutet, Jürgen Germann, et al.
Journal of Medicinal Chemistry
|
August 29, 2012
Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer
J Jean Cui, Michele McTigue, Mitchell Nambu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 10, 2020
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer
Mi Ran Yun, Dong Hwi Kim, Seok-Young Kim, et al.
Journal of Medicinal Chemistry
|
August 5, 2011
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)
J Jean Cui, Michelle Tran-Dubé, Hong Shen, et al.
Journal of Bone Oncology
|
December 29, 2018
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
R E Coleman, M Collinson, W Gregory, et al.
Journal of Medicinal Chemistry
|
April 20, 2018
Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors
Sharan K Bagal, Kiyoyuki Omoto, David C Blakemore, et al.
Cancer Discovery
|
August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
Neurology
|
December 23, 2024
Comparison of Plasma p-tau217 and [<sup>18</sup>F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia
Kely Monica Quispialaya, Joseph Therriault, Antonio Aliaga, et al.
Journal of Medicinal Chemistry
|
May 14, 2014
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations
Ted W Johnson, Paul F Richardson, Simon Bailey, et al.
The Lancet. Oncology
|
December 2, 2024
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus
Vincent J Cogliano, Emanuela Corsini, Agnès Fournier, et al.
Page
of 34